Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity

Journal of Immunology

Volumn 187, Issue 5, 2011, Pages 2824-2833

  Falkenburg, Willem J J ^a   Melenhorst, J Joseph ^a   Van De Meent, Marian ^b   Kester, Michel G D ^b   Hombrink, Pleun ^b   Heemskerk, Mirjam H M ^b   Hagedoorn, Renate S ^b   Gostick, Emma ^c   Price, David A ^c   Falkenburg, J H Frederik ^b   Barrett, A John ^a   Jedema, Inge ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD8 ANTIGEN; HLA A ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG; WILMS TUMOR PROTEIN; CANCER VACCINE; HLA A*02 ANTIGEN; HLA-A*02 ANTIGEN; WT1 PROTEIN;

ALLOGENEIC RESTRICTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELL CLONE; CELL ISOLATION; CELL SELECTION; CELL SPECIFICITY; CONTROLLED STUDY; DONOR; EX VIVO STUDY; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; THYMOCYTE; ALLOTRANSPLANTATION; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

AUTOANTIGENS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FLOW CYTOMETRY; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; TRANSPLANTATION, HOMOLOGOUS; WT1 PROTEINS;

EID: 80052688434     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100852     Document Type: Article

References (59)

1. Miwa, H., M. Beran, and G. F. Saunders. 1992. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6: 405-409.
2. Menssen, H. D., H. J. Renkl, U. Rodeck, J. Maurer, M. Notter, S. Schwartz, R. Reinhardt, and E. Thiel. 1995. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9: 1060-1067.
3. Inoue, K., H. Ogawa, Y. Sonoda, T. Kimura, H. Sakabe, Y. Oka, S. Miyake, H. Tamaki, Y. Oji, T. Yamagami, et al. 1997. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89: 1405-1412. (Pubitemid 27080005)
4. Yong, A. S., K. Keyvanfar, R. Eniafe, B. N. Savani, K. Rezvani, E. M. Sloand, J. M. Goldman, and A. J. Barrett. 2008. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22: 1721-1727.
5. Morita, Y., Y. Heike, M. Kawakami, O. Miura, S. Nakatsuka, M. Ebisawa, S. Mori, R. Tanosaki, T. Fukuda, S. W. Kim, et al. 2006. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int. J. Cancer 119: 1360-1367. (Pubitemid 44258812)
6. Rezvani, K., A. S. Yong, B. N. Savani, S. Mielke, K. Keyvanfar, E. Gostick, D. A. Price, D. C. Douek, and A. J. Barrett. 2007. Graft-versus- leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 110: 1924-1932. (Pubitemid 47443906)
7. Rezvani, K., J. M. Brenchley, D. A. Price, Y. Kilical, E. Gostick, A. K. Sewell, J. Li, S. Mielke, D. C. Douek, and A. J. Barrett. 2005. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin. Cancer Res. 11: 8799-8807. (Pubitemid 43005931)
8. Gao, L., I. Bellantuono, A. Elsässer, S. B. Marley, M. Y. Gordon, J. M. Goldman, and H. J. Stauss. 2000. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198-2203. (Pubitemid 30167714)
9. Weber, G., J. Karbach, S. Kuçi, H. Kreyenberg, A. Willasch, E. Koscielniak, T. Tonn, T. Klingebiel, W. S. Wels, E. Jäger, and P. Bader. 2009. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 23: 1634-1642.
10. Doubrovina, E. S., M. M. Doubrovin, S. Lee, J. H. Shieh, G. Heller, E. Pamer, and R. J. O'Reilly. 2004. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Clin. Cancer Res. 10: 7207-7219. (Pubitemid 39487707)
11. Ohminami, H., M. Yasukawa, and S. Fujita. 2000. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95: 286-293. (Pubitemid 30017254)
12. Xue, S. A., L. Gao, D. Hart, R. Gillmore, W. Qasim, A. Thrasher, J. Apperley, B. Engels, W. Uckert, E. Morris, and H. Stauss. 2005. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106: 3062-3067. (Pubitemid 41565901)
13. Thomas, S., S. A. Xue, M. Cesco-Gaspere, E. San José, D. P. Hart, V. Wong, R. Debets, B. Alarcon, E. Morris, and H. J. Stauss. 2007. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J. Immunol. 179: 5803-5810.
14. Xue, S. A., L. Gao, S. Thomas, D. P. Hart, J. Z. Xue, R. Gillmore, R. H. Voss, E. Morris, and H. J. Stauss. 2010. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 95: 126-134.
15. Oka, Y., O. A. Elisseeva, A. Tsuboi, H. Ogawa, H. Tamaki, H. Li, Y. Oji, E. H. Kim, T. Soma, M. Asada, et al. 2000. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51: 99-107. (Pubitemid 30150969)
16. Oka, Y., A. Tsuboi, O. A. Elisseeva, K. Udaka, and H. Sugiyama. 2002. WT1 as a novel target antigen for cancer immunotherapy. Curr. Cancer Drug Targets 2: 45-54. (Pubitemid 34627378)
17. Scheibenbogen, C., A. Letsch, E. Thiel, A. Schmittel, V. Mailaender, S. Baerwolf, D. Nagorsen, and U. Keilholz. 2002. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100: 2132-2137. (Pubitemid 35001248)
18. Koesters, R., M. Linnebacher, J. F. Coy, A. Germann, Y. Schwitalle, P. Findeisen, and M. Von Knebel Doeberitz. 2004. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int. J. Cancer 109: 385-392. (Pubitemid 38252767)
19. Asemissen, A. M., U. Keilholz, S. Tenzer, M. Müller, S. Walter, S. Stevanovic, H. Schild, A. Letsch, E. Thiel, H. G. Rammensee, and C. Scheibenbogen. 2006. Identification of a highly immunogenic HLA-A*01- binding T cell epitope of WT1. Clin. Cancer Res. 12: 7476-7482. (Pubitemid 46095423)
20. Oka, Y., A. Tsuboi, M. Murakami, M. Hirai, N. Tominaga, H. Nakajima, O. A. Elisseeva, T. Masuda, A. Nakano, M. Kawakami, et al. 2003. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) orMDSwith myelofibrosis. Int. J. Hematol. 78: 56-61. (Pubitemid 36899903)
21. Mailänder, V., C. Scheibenbogen, E. Thiel, A. Letsch, I. W. Blau, and U. Keilholz. 2004. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18: 165-166. (Pubitemid 38159453)
22. Rezvani, K., A. S. Yong, S. Mielke, B. N. Savani, L. Musse, J. Superata, B. Jafarpour, C. Boss, and A. J. Barrett. 2008. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111: 236-242.
23. Keilholz, U., A. Letsch, A. Busse, A. M. Asemissen, S. Bauer, I. W. Blau, W. K. Hofmann, L. Uharek, E. Thiel, and C. Scheibenbogen. 2009. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113: 6541-6548.
24. Oka, Y., A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, et al. 2004. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA 101: 13885-13890. (Pubitemid 39298502)
25. Hashii, Y., E. Sato, H. Ohta, Y. Oka, H. Sugiyama, and K. Ozono. 2010. WT1 peptide immunotherapy for cancer in children and young adults. Pediatr. Blood Cancer 55: 352-355.
26. Maslak, P. G., T. Dao, L. M. Krug, S. Chanel, T. Korontsvit, V. Zakhaleva, R. Zhang, J. D. Wolchok, J. Yuan, J. Pinilla-Ibarz, et al. 2010. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T cell responses in patients with complete remission from acute myeloid leukemia (AML). Blood 116: 171-179.
27. Yasukawa, M., H. Fujiwara, T. Ochi, K. Suemori, H. Narumi, T. Azuma, and K. Kuzushima. 2009. Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome. Am. J. Hematol. 84: 314-315.
28. Van Tendeloo, V. F., A. Van de Velde, A. Van Driessche, N. Cools, S. Anguille, K. Ladell, E. Gostick, K. Vermeulen, K. Pieters, G. Nijs, et al. 2010. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. USA 107: 13824-13829.
29. Narita, M., N. Tochiki, A. Saitoh, N. Watanabe, M. Kaji, N. Satoh, A. Yamahira, T. Nakamura, M. Masuko, T. Furukawa, et al. 2009. Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA. Med. Oncol. 26: 429-436.
30. Wolfl, M., J. Kuball, W. Y. Ho, H. Nguyen, T. J. Manley, M. Bleakley, and P. D. Greenberg. 2007. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110: 201-210. (Pubitemid 47026836)
31. Ho, W. Y., H. N. Nguyen, M. Wolfl, J. Kuball, and P. D. Greenberg. 2006. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. J. Immunol. Methods 310: 40-52. (Pubitemid 43375974)
32. Wang, X., A. Schmitt, B. Chen, X. Xu, J. Mani, M. Linnebacher, M. Freund, and M. Schmitt. 2010. Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Exp. Hematol. 38: 1066-1073.
33. Mundlos, S., J. Pelletier, A. Darveau, M. Bachmann, A. Winterpacht, and B. Zabel. 1993. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 119: 1329-1341. (Pubitemid 23358597)
34. Baird, P. N., and P. J. Simmons. 1997. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp. Hematol. 25: 312-320. (Pubitemid 27236656)
35. Ramani, P., and J. K. Cowell. 1996. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours. J. Pathol. 179: 162-168. (Pubitemid 26201584)
36. Amir, A. L., L. J. D'Orsogna, D. L. Roelen, M. M. Van Loenen, R. S. Hagedoorn, R. De Boer, M. A. Van der Hoorn, M. G. Kester, I. I. Doxiadis, J. H. Falkenburg, et al. 2010. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 115: 3146-3157.
37. Melenhorst, J. J., A. M. Leen, C. M. Bollard, M. F. Quigley, D. A. Price, C. M. Rooney, M. K. Brenner, A. J. Barrett, and H. E. Heslop. 2010. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116: 4700-4702.
38. Sadovnikova, E., L. A. Jopling, K. S. Soo, and H. J. Stauss. 1998. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol. 28: 193-200. (Pubitemid 28048290)
39. Wilde, S., D. Sommermeyer, B. Frankenberger, M. Schiemann, S. Milosevic, S. Spranger, H. Pohla, W. Uckert, D. H. Busch, and D. J. Schendel. 2009. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 114: 2131-2139.
40. Krönig, H., K. Hofer, H. Conrad, P. Guilaume, J. Müller, M. Schiemann, V. Lennerz, A. Cosma, C. Peschel, D. H. Busch, et al. 2009. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int. J. Cancer 125: 649-655.
41. Savage, P., L. Gao, K. Vento, P. Cowburn, S. Man, N. Steven, G. Ogg, A. McMichael, A. Epenetos, E. Goulmy, and H. J. Stauss. 2004. Use of B cell-bound HLA-A2 class Imonomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103: 4613-4615. (Pubitemid 38745991)
42. Münz, C., R. Obst, W. Osen, S. Stevanović, and H. G. Rammensee. 1999. Alloreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 162: 25-34. (Pubitemid 29018900)
43. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96. (Pubitemid 26332731)
44. Price, D. A., J. M. Brenchley, L. E. Ruff, M. R. Betts, B. J. Hill, M. Roederer, R. A. Koup, S. A. Migueles, E. Gostick, L. Wooldridge, et al. 2005. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J. Exp. Med. 202: 1349-1361. (Pubitemid 41668738)
45. Rodenko, B., M. Toebes, S. R. Hadrup, W. J. Van Esch, A. M. Molenaar, T. N. Schumacher, and H. Ovaa. 2006. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat. Protoc. 1: 1120-1132.
46. Oosten, L. E., E. Blokland, A. G. Van Halteren, J. Curtsinger, M. F. Mescher, J. H. Falkenburg, T. Mutis, and E. Goulmy. 2004. Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 104: 224-226. (Pubitemid 38879861)
47. Heemskerk, M. H., R. A. De Paus, E. G. Lurvink, F. Koning, A. Mulder, R. Willemze, J. J. Van Rood, and J. H. Falkenburg. 2001. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc. Natl. Acad. Sci. USA 98: 6806-6811. (Pubitemid 32538298)
48. Melenhorst, J. J., S. R. Solomon, A. Shenoy, N. F. Hensel, J. P. McCoy, Jr., K. Keyvanfar, and A. J. Barrett. 2006. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J. Immunother. 29: 436-443, discussion 365-366.
49. Lee, A. W., T. Truong, K. Bickham, J. F. Fonteneau, M. Larsson, I. Da Silva, S. Somersan, E. K. Thomas, and N. Bhardwaj. 2002. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl 4): A8-A22. (Pubitemid 35449402)
50. Jonuleit, H., U. Kühn, G. Müller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27: 3135-3142. (Pubitemid 28018007)
51. Douek, D. C., M. R. Betts, J. M. Brenchley, B. J. Hill, D. R. Ambrozak, K. L. Ngai, N. J. Karandikar, J. P. Casazza, and R. A. Koup. 2002. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J. Immunol. 168: 3099-3104. (Pubitemid 34211693)
52. Jedema, I., R. M. Barge, R. Willemze, and J. H. Falkenburg. 2003. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment. Leukemia 17: 576-584. (Pubitemid 36395652)
53. Melenhorst, J. J., P. Scheinberg, P. K. Chattopadhyay, E. Gostick, K. Ladell, M. Roederer, N. F. Hensel, D. C. Douek, A. J. Barrett, and D. A. Price. 2009. High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood 113: 2238-2244.
54. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227-2234. (Pubitemid 29288845)
55. Felix, N. J., D. L. Donermeyer, S. Horvath, J. J. Walters, M. L. Gross, A. Suri, and P. M. Allen. 2007. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat. Immunol. 8: 388-397. (Pubitemid 46745414)
56. Huseby, E. S., F. Crawford, J. White, J. Kappler, and P. Marrack. 2003. Negative selection imparts peptide specificity to the mature T cell repertoire. Proc. Natl. Acad. Sci. USA 100: 11565-11570. (Pubitemid 37205976)
57. Heath, W. R., K. P. Kane, M. F. Mescher, and L. A. Sherman. 1991. Alloreactive T cells discriminate among a diverse set of endogenous peptides. Proc. Natl. Acad. Sci. USA 88: 5101-5105. (Pubitemid 21914691)
58. Daniel, C., S. Horvath, and P. M. Allen. 1998. A basis for alloreactivity: MHC helical residues broaden peptide recognition by the TCR. Immunity 8: 543-552. (Pubitemid 28264745)
59. Macdonald, W. A., Z. Chen, S. Gras, J. K. Archbold, F. E. Tynan, C. S. Clements, M. Bharadwaj, L. Kjer-Nielsen, P. M. Saunders, M. C. Wilce, et al. 2009. T cell allorecognition via molecular mimicry. Immunity 31: 897-908.